Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Eur Cell Mater ; 20: 13-23, 2010 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-20597062

RESUMEN

Platelet-rich plasma (PRP) is used clinically in liquid or gel form to promote tissue repair. Because of the poor mechanical properties, conventional PRP is often difficult to handle when used in clinical settings and requires secure implantation in a specific site, otherwise when released growth factors could be washed out during an operation. In this study, we analyzed the end product of a recently developed commercially available system (FIBRINET), which is a dense pliable, platelet-rich fibrin matrix (PRFM). We characterized the mechanical properties of PRFM and tested whether PRFM releases growth factors and whether released factors induce the proliferation of mesenchymal stem cells (MSC). Mechanical properties as well as platelet distribution were evaluated in PRFM. PRFM demonstrated robust mechanical properties, with a tear elastic modulus of 937.3 +/- 314.6 kPa, stress at a break of 1476.0 +/- 526.3 kPa, and an elongation at break of 146.3 +/- 33.8 %. PRFM maintained its mechanical properties throughout the testing process. Microscopic observations showed that the platelets were localized on one side of the matrix. Elevated levels of PDGF-AA, PDGF-AB, EGF, VEGF, bFGF and TGF-beta1 were measured in the day 1-conditioned media (CM) of PRFM and growth factor levels decreased thereafter. BMP2 and BMP7 were not detectable. MSC culture media supplemented with 20% PRFM-CM stimulated MSC cell proliferation; at 24 and 48 hours the induction of the proliferation was significantly greater than the induction obtained with media supplemented with 20% foetal bovine serum. The present study shows that the production of a dense, physically robust PRFM made through high-speed centrifugation of intact platelets and fibrin in the absence of exogenous thrombin yields a potential tool for accelerating tissue repair.


Asunto(s)
Fibrina/metabolismo , Plasma Rico en Plaquetas/metabolismo , Proliferación Celular , Medios de Cultivo Condicionados , Humanos , Células Madre Mesenquimatosas/citología , Células Madre Mesenquimatosas/metabolismo , Microscopía Electrónica de Rastreo , Microscopía Fluorescente , Factor de Crecimiento Derivado de Plaquetas/metabolismo , Plasma Rico en Plaquetas/citología
2.
J Biomed Mater Res A ; 105(4): 1019-1033, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-27943619

RESUMEN

Demineralized bone matrix (DBM) is a natural, collagen-based, osteoinductive biomaterial. Nevertheless, there are conflicting reports on the efficacy of this product. The purpose of this study was to evaluate whether DBM collagen structure is affected by particle size and can influence DBM cytocompatibility and osteoinductivity. Sheep cortical bone was ground and particles were divided in three fractions with different sizes, defined as large (L, 1-2 mm), medium (M, 0.5-1 mm), and small (S, <0.5 mm). After demineralization, the chemical-physical analysis clearly showed a particle size-dependent alteration in collagen structure, with DBM-M being altered but not as much as DBM-S. DBM-M displayed a preferable trend in almost all biological characteristics tested, although all DBM particles revealed an optimal cytocompatibility. Subcutaneous implantation of DBM particles into immunocompromised mice resulted in bone induction only for DBM-M. When sheep MSC were seeded onto particles before implantation, all DBM particles were able to induce new bone formation with the best incidence for DBM-M and DBM-S. In conclusion, the collagen alteration in DBM-M is likely the best condition to promote bone induction in vivo. Furthermore, the choice of 0.5-1 mm particles may enable to obtain more efficient and consistent results among different research groups in bone tissue-engineering applications. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 1019-1033, 2017.


Asunto(s)
Matriz Ósea/citología , Colágeno/química , Células Madre Mesenquimatosas/metabolismo , Osteogénesis , Animales , Matriz Ósea/trasplante , Ratones , Ratones SCID , Ovinos
3.
J Control Release ; 168(2): 225-37, 2013 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-23524189

RESUMEN

Mesenchymal stem cells (MSC) have the unique ability to home and engraft in tumor stroma. These features render them potentially a very useful tool as targeted delivery vehicles which can deliver therapeutic drugs to the tumor stroma. In the present study, we investigate whether fluorescent core-shell PMMA nanoparticles (FNPs) post-loaded with a photosensitizer, namely meso-tetrakis (4-sulfonatophenyl) porphyrin (TPPS) and uploaded by MSC could trigger osteosarcoma (OS) cell death in vitro upon specific photoactivation. In co-culture studies we demonstrate using laser confocal microscopy and time lapse imaging, that only after laser irradiation MSC loaded with photosensitizer-coated fluorescent NPs (TPPS@FNPs) undergo cell death and release reactive oxygen species (ROS) which are sufficient to trigger cell death of all OS cells in the culture. These results encourage further studies aimed at proving the efficacy of this novel tri-component system for PDT applications.


Asunto(s)
Neoplasias Óseas/tratamiento farmacológico , Células Madre Mesenquimatosas , Osteosarcoma/tratamiento farmacológico , Fotoquimioterapia , Fármacos Fotosensibilizantes/administración & dosificación , Porfirinas/administración & dosificación , Apoptosis/efectos de los fármacos , Neoplasias Óseas/metabolismo , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Sistemas de Liberación de Medicamentos , Humanos , Nanopartículas/administración & dosificación , Osteosarcoma/metabolismo , Especies Reactivas de Oxígeno/metabolismo
4.
Biomed Res Int ; 2013: 549762, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24073409

RESUMEN

PURPOSE: This study evaluated the efficacy of a regenerative approach using mesenchymal stem cells (MSCs) and CAD-CAM customized pure and porous hydroxyapatite (HA) scaffolds to replace the temporomandibular joint (TMJ) condyle. METHODS: Pure HA scaffolds with a 70% total porosity volume were prototyped using CAD-CAM technology to replace the two temporomandibular condyles (left and right) of the same animal. MSCs were derived from the aspirated iliac crest bone marrow, and platelets were obtained from the venous blood of the sheep. Custom-made surgical guides were created by direct metal laser sintering and were used to export the virtual planning of the bone cut lines into the surgical environment. Sheep were sacrificed 4 months postoperatively. The HA scaffolds were explanted, histological specimens were prepared, and histomorphometric analysis was performed. RESULTS: Analysis of the porosity reduction for apposition of newly formed bone showed a statistically significant difference in bone formation between condyles loaded with MSC and condyles without (P < 0.05). The bone ingrowth (BI) relative values of split-mouth comparison (right versus left side) showed a significant difference between condyles with and without MSCs (P < 0.05). Analysis of the test and control sides in the same animal using a split-mouth study design was performed; the condyle with MSCs showed greater bone formation. CONCLUSION: The split-mouth design confirmed an increment of bone regeneration into the HA scaffold of up to 797% upon application of MSCs.


Asunto(s)
Plaquetas/química , Cerámica/farmacología , Diseño Asistido por Computadora , Durapatita/farmacología , Cóndilo Mandibular/fisiología , Células Madre Mesenquimatosas/citología , Andamios del Tejido/química , Animales , Cartílago/citología , Cartílago/efectos de los fármacos , Geles , Cóndilo Mandibular/efectos de los fármacos , Trasplante de Células Madre Mesenquimatosas , Células Madre Mesenquimatosas/efectos de los fármacos , Células Madre Mesenquimatosas/metabolismo , Porosidad , Ovinos , Ingeniería de Tejidos
5.
J Bone Joint Surg Br ; 94(6): 836-41, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22628602

RESUMEN

We retrospectively reviewed 101 consecutive patients with 114 femoral tumours treated by massive bone allograft at our institution between 1986 and 2005. There were 49 females and 52 males with a mean age of 20 years (4 to 74). At a median follow-up of 9.3 years (2 to 19.8), 36 reconstructions (31.5%) had failed. The allograft itself failed in 27 reconstructions (24%). Mechanical complications such as delayed union, fracture and failure of fixation were studied. The most adverse factor on the outcome was the use of intramedullary nails, followed by post-operative chemotherapy, resection length > 17 cm and age > 18 years at the time of intervention. The simultaneous use of a vascularised fibular graft to protect the allograft from mechanical complications improved the outcome, but the use of intramedullary cementing was not as successful. In order to improve the strength of the reconstruction and to advance the biology of host-graft integration, we suggest avoiding the use of intramedullary nails and titanium plates, but instead using stainless steel plates, as these gave better results. The use of a supplementary vascularised fibular graft should be strongly considered in adult patients with resection > 17 cm and in those who require post-operative chemotherapy.


Asunto(s)
Trasplante Óseo/métodos , Neoplasias Femorales/cirugía , Sarcoma/cirugía , Adolescente , Adulto , Factores de Edad , Anciano , Clavos Ortopédicos/efectos adversos , Placas Óseas , Trasplante Óseo/efectos adversos , Quimioterapia Adyuvante/efectos adversos , Niño , Preescolar , Femenino , Fracturas del Fémur/etiología , Neoplasias Femorales/tratamiento farmacológico , Supervivencia de Injerto , Humanos , Masculino , Persona de Mediana Edad , Oseointegración , Osteotomía/métodos , Estudios Retrospectivos , Factores de Riesgo , Sarcoma/tratamiento farmacológico , Resultado del Tratamiento , Adulto Joven
6.
Injury ; 39 Suppl 2: S65-72, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18804576

RESUMEN

UNLABELLED: Massive bone allografts are frequently used in orthopaedic reconstructive surgery. However the failure rate at long term follow-up is around 25%. AIM: Stimulation of allograft incorporation. MATERIALS AND METHODS: In order to stimulate bone remodeling of an allograft we applied recombinant human osteogenic protein-1 (rh-OP-1, also know as bone morphogenetic protein-7, BMP-7) to a long bone critical size defect sheep model. In nine sheep we created a 3 cm osteoperiosteal metatarsal defect replaced with a structural allograft alone (control group, 4 animals), or an allograft added with rh-BMP-7 (BMP group, 5 animals). Radiographic, mechanical, histological and histomorphometric analysis were performed. RESULTS: X-rays in the BMP group showed a better and faster callus formation, compared to the control group within the first 8 weeks after surgery. After 16 weeks there was a higher evidence of bone remodeling in the BMP group. Radiographic healing at junction sites was more evident in the BMP group at 4, 8 and 16 weeks. Mechanical testing on screw extraction showed no statistical differences between the two groups and histomorphometry showed no difference in terms of newly formed bone inside the allograft as well. The resorption rate of the graft was higher in the BMP group in comparison to the control group. The penetration of newly formed vessels was significantly higher in the BMP group. CONCLUSIONS: These findings indicate that BMP-7 added to a structural bone allograft inducing early remodeling of the graft through stimulation of neo-angiogenesis and osteoclastic activity, without negative effects in mechanical strength and clinical outcome.


Asunto(s)
Proteína Morfogenética Ósea 7/administración & dosificación , Remodelación Ósea/efectos de los fármacos , Trasplante Óseo/métodos , Animales , Proteína Morfogenética Ósea 7/farmacología , Callo Óseo/efectos de los fármacos , Modelos Animales de Enfermedad , Huesos Metatarsianos/diagnóstico por imagen , Huesos Metatarsianos/efectos de los fármacos , Huesos Metatarsianos/lesiones , Huesos Metatarsianos/patología , Huesos Metatarsianos/cirugía , Osteotomía , Radiografía , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacología , Ovinos
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda